These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11367449)

  • 1. Hydroxyurea: what it is. New Mexico AIDS InfoNet.
    Newsline People AIDS Coalit N Y; 1998 Mar; ():15. PubMed ID: 11367449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ddI, d4T, Hydroxyurea: new pancreatitis warning.
    AIDS Treat News; 1999 Nov; (No 331):1-3. PubMed ID: 11367125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard treatments for HIV, Spring 1997.
    Smith D
    AIDS Treat News; 1997 Apr; (No 269):4-5. PubMed ID: 11364255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea may enhance effectiveness of anti-HIV regimens presently in use.
    Murphy MJ
    Fac Notes (New Orleans La); 1998; 10(2):1-2. PubMed ID: 11365124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
    Lori F; Lisziewicz J
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S193-7. PubMed ID: 10860905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea--ever more fascinating.
    Horn T
    Notes Undergr; 1998; (No 37):1-3, 9. PubMed ID: 11365816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea for HIV?
    Treat Rev; 1998; (No 28):10-2. PubMed ID: 11365419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What they say about complementary drugs.
    Posit Aware; 1999; 10(1):45. PubMed ID: 11366524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Hydroxyurea for real?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advantages of HIV treatment with Hydrea (Hydroxyurea).
    Baker B
    Posit Aware; 1998; 9(5):54. PubMed ID: 11365897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine+ddI+Hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles.
    AIDS Treat News; 1999 Dec; (No 332):8. PubMed ID: 11367131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea.
    Gortner C
    BETA; 1998 Oct; ():7. PubMed ID: 11365996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment -- study results.
    Treat Rev; 1996 Dec; (No 23):4-11. PubMed ID: 11364282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ddI: FDA approves once-daily dosing. Food and Drug Administration.
    James JS
    AIDS Treat News; 1999 Nov; (No 330):1. PubMed ID: 11367169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of hydroxyurea in heavily pretreated patients with HIV infection.
    Hermans P; De Wit S; Sommereijns B; O'Doherty E; Clumeck N
    Antivir Ther; 1999; 4 Suppl 3():19-22. PubMed ID: 16021867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
    Stebbing J; Nelson M; Orkin C; Mandalia S; Bower M; Pozniak A; Gazzard B
    J Antimicrob Chemother; 2004 Mar; 53(3):501-5. PubMed ID: 14762056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea under study.
    Posit Aware; 1995; ():5. PubMed ID: 11362569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New data intensifies interest in hydroxyurea.
    Santiago LG
    GMHC Treat Issues; 1995 Sep; 9(9):1, 3-4. PubMed ID: 11362902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
    Paton NI; Aboulhab J
    HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.